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Background: 3-phosphoinositide-dependent protein kinase-1 (PDK1) functions downstream of phosphoinositide
3-kinase (PIK3) and activates members of the AGC family of protein kinases that are known to play crucial roles in
physiological processes associated with cell metabolism, growth, proliferation and survival. Changes in the
expression and activity of PDK1 and several AGC kinases have been linked to human disease, including cancer.
Methods: We used immunohistochemical analysis to determine PDK1 expression in 241 tumors from patients with
breast cancer in which we had previously analyzed PIK3CA mutation status.
Results: Moderate or high expression of PDK1 was observed in 213 of the 241 cases (88%). There was no
correlation between PIK3CA mutation status and PDK1 overexpression.
Conclusion: Our findings indicate that PDK1 is independently activated in breast cancer and not only as part of the
PIK3CA pathway, suggesting that PDK1 plays a specific and distinct role from the canonical PIK3/Akt pathway and
promotes oncogenesis independently of AKT. Our data implicate PDK-1 and downstream components of the PDK-1
signaling pathway as promising therapeutic targets for the treatment of breast cancer.
Keywords: PDK1, PIK3CA, Breast cancerThe protein kinase 3-phosphoinositide-dependent protein
kinase-1 (PDK1) plays a key role in signaling pathways acti-
vated by several growth factors and hormones. PDK1 func-
tions downstream of phosphoinositide 3-kinase (PIK3) and
activates members of the AGC family of protein kinases
such as protein kinase B (Akt), protein kinase C (PKC), p70
ribosomal protein S6 kinases, and serum glucocorticoid-
dependent kinase by phosphorylating serine/threonine resi-
dues in the activation loop. AGC kinases are known to play
crucial roles in the regulation of various physiological pro-
cesses relevant to metabolism, growth, proliferation, and
survival.
The first evidence that PDK1 might be a viable target
in cancer came in 2005 when Bayascas et al. [1] gener-
ated transgenic mice that were hypomorphic for PDK1.
These mice were crossed with tumorigenic heterozy-
gous PTEN +/- mice and the resulting mice with defi-
cient PDK1 levels had a reduced prevalence of tumor
development. Subsequent studies demonstrated the roleCorrespondence: ruza.arsenic@charite.de
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PDK1 appears to play a decisive role in the development
of breast cancer [2].
Increased PDK1 expression has also been reported in
45% of patients with acute myeloid leukemia, and PDK1
seems to be a viable target in head and neck cancer, mul-
tiple myeloma, pancreatic cancer, and colorectal cancer
[3-7]. Vasudevan et al. [8] reported that a subset of breast
cancer cell lines with mutations in PIK3CA displayed a re-
duced dependence on Akt for tumorigenicity, and instead
relied on PDK1-dependent activation of another AGC kin-
ase, SGK-3. Breast cancers are known to be a group of di-
verse diseases, and cellular heterogeneity has been shown
to affect disease-free survival in patients with breast can-
cer [9]. For example, expression of CARM1 varies widely
among different molecular subtypes of breast cancer, and
overexpression of CARM1 is associated with invasive can-
cer and a poor prognosis [10]. Molecules such as CARM1
may have potential clinical applications in prognostic
stratification and therapeutic molecular targeting.
There is accumulating evidence that PDK1 is overex-
pressed in particular cancer settings and activates cancerhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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These findings suggest that PDK1 is not just an Akt-
activating player, but rather an important oncogenetic
regulator and a potential therapeutic target in cancer. Re-
cently, it has been shown that PDK1 regulates anchorage-
independent growth, resistance to several anticancer drugs,
and tumor formation in breast cancer cells–not only in tu-
mors harboring PIK3CA mutations, but also in the absence
of these genetic alterations [11].
This study aimed to answer the following questions: (1)
Is PDK1 overexpressed in breast cancer and to what ex-
tent? (2) Is there any correlation between PDK1 overex-
pression and PIK3CA mutations?
To address these questions, we examined the phosphor-
ylation status of PDK1 in a group of tumors in which we
had previously analyzed PIK3CA mutations [12]. Four tis-
sue microarrays were generated from formalin-fixed and
paraffin-embedded (FFPE) specimens using a precision in-
strument (Beecher instruments, Silver Spring, MD, USA).
A representative tumor-bearing slide was selected for each
case by a board certified pathologist with a special interest
in breast pathology (RA). Typical tumor areas were
marked on the respective H&E slides. Subsequently two
tissue cylinders of 1.5 mm diameter were punched from
each tumor-bearing donor block and transferred to a tis-
sue microarray paraffin block. For immunohistochemistry,
3-μm paraffin sections were cut and incubated with anti-
body to pPDK1. Omission of the primary antibody served
as the negative control. The primary antibody used in thisC D
A B
Figure 1 Immunohistochemical expression of PDK1 (3-phosphoinosit
with strong immunostaining, score 3, B-tumor cells with moderate immun
D-tumor cells negative, score 0.study was purchased from Cell Signaling Technology
Inc. (Beverly, MA) and was highly validated by the manu-
facturer (pPDK1, S241, 1 : 50 dilution). The overall intensity
of immunohistochemical staining on ductal and lobular re-
gions within each tissue was scored visually and graded as
follows: 0, negative staining; 1, weak staining; 2, moderate
staining; and 3, intensive staining. A score of 2 or greater
was required for a tissue to be classified as positive for phos-
phorylation. Representative images showing staining pat-
terns corresponding to each score are shown in Figure 1.
Moderate or high expression of PDK1 was observed in
213 of the 241 cases (88%). PIK3CA mutations were iden-
tified in 15.8% of cases in the same patient collective.
There was no correlation between PIK3CA mutation sta-
tus and PDK1 overexpression.
The fact that some cases without PIK3CA mutations
had a moderate or high expression of PDK1 suggests that
PDK1 can be independently activated in breast cancer and
not only as part of the PIK3CA pathway. Our results indi-
cate that PDK1 plays a specific role distinct from the ca-
nonical PIK3/Akt pathway.
To the best of our knowledge this study is the first to
compare PIK3CA mutation status and PDK1 expression
in tissues from the same tumor group. The results of our
study suggest that the PDK-1 signaling pathway might be
a promising therapeutic target for the treatment of breast
cancer and that PDK1 expression should be tested in
addition to PIK3CA status in patients with breast cancer
prior to beginning therapy.ide-dependent protein kinase-1) in breast cancer. A-tumor cells
ostaining-score2, C-tumor cells with weak immunostaining, score 1,
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PDK1: 3-phosphoinositide-dependent protein kinase-1;
PIK3CA: phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha.
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